PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2553586-5 1989 In combination with other cell stimuli, NaF showed modulatory effects, such as an enhanced formation of the leukotrienes when FMLP, opsonized zymosan, PMA, and arachidonic acid were applied as stimuli. Leukotrienes 108-120 formyl peptide receptor 1 Homo sapiens 126-130 2515549-2 1989 After heat shock treatment the generation of leukotrienes induced by the Ca(++)-ionophore A23187, fMLP or opsonized zymosan was inhibited in a time and temperature dependent manner (preincubation phase) as was measured by HPLC-analysis. Leukotrienes 45-57 formyl peptide receptor 1 Homo sapiens 98-102 2833556-0 1988 Leukotriene production in human neutrophils primed by recombinant human granulocyte/macrophage colony-stimulating factor and stimulated with the complement component C5A and FMLP as second signals. Leukotrienes 0-11 formyl peptide receptor 1 Homo sapiens 174-178 2789431-3 1989 In contrast, strong chemotactic migration was elicited in PMN and MO with the tripeptide N-formyl-methionyl-leucyl-phenylalanine (FMLP) and in T cells when complement split product C5a and leukotriene B4 (LTB4) were used as chemotaxins. Leukotrienes 189-200 formyl peptide receptor 1 Homo sapiens 130-134 2735951-6 1989 Pretreatment of the cells with 40 microM ethylmercurithiosalicylate (merthiolate) enhanced the leukotriene formation by 100 nM FMLP about 40-fold, by 280 nM C3a about 120-fold and by 1 microM PAF about 14-fold. Leukotrienes 95-106 formyl peptide receptor 1 Homo sapiens 127-131 2735951-11 1989 The FMLP/merthiolate-induced leukotriene formation was modulated by prostanoids. Leukotrienes 29-40 formyl peptide receptor 1 Homo sapiens 4-8 3040727-4 1987 Identical average onset times (2.4 s) and closely comparable values for the apparent first-order rate constant (kapp) for the induction of NADPH-oxidase activity (0.21-0.29 s-1) were obtained following stimulation with fMLP, C5a, platelet-activating factor, or leukotriene B4, suggesting that different agonists act through a common transduction sequence. Leukotrienes 261-272 formyl peptide receptor 1 Homo sapiens 219-223 3001181-3 1986 The maximal response to FMLP occurred within 10 min, and the sum of the two classes of leukotrienes generated was about 1/6 that obtained from monocytes stimulated with calcium ionophore A23187. Leukotrienes 87-99 formyl peptide receptor 1 Homo sapiens 24-28 3001181-7 1986 The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion. Leukotrienes 4-15 formyl peptide receptor 1 Homo sapiens 253-266 3001181-7 1986 The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion. Leukotrienes 4-15 formyl peptide receptor 1 Homo sapiens 253-257 3031568-1 1987 Leukotriene (LT) synthesis triggered with ionophore A23187 or inflammatory stimuli (PAF, fMLP) in human polymorphonuclear leukocytes (PMNL) was markedly decreased by SIN-1, an active metabolite of molsidomine. Leukotrienes 0-11 formyl peptide receptor 1 Homo sapiens 89-93 3031568-1 1987 Leukotriene (LT) synthesis triggered with ionophore A23187 or inflammatory stimuli (PAF, fMLP) in human polymorphonuclear leukocytes (PMNL) was markedly decreased by SIN-1, an active metabolite of molsidomine. Leukotrienes 13-15 formyl peptide receptor 1 Homo sapiens 89-93 3001181-4 1986 The requirement for cytochalasin B in order for FMLP, but not the calcium ionophore, to stimulate leukotriene generation is compatible with the ability of cytochalasin B to augment in other cells certain stimulus-specific transmembrane responses that are not dependent on the integrity of the cytoskeleton. Leukotrienes 98-109 formyl peptide receptor 1 Homo sapiens 48-52 3001181-5 1986 Resolution by reverse phase high performance liquid chromatography of the products released from monocytes pretreated with cytochalasin B and stimulated with FMLP or calcium ionophore yielded a single peak of immunoreactive LTB4 eluting at the same retention time as the synthetic standard; immunoreactive C-6 sulfidopeptide leukotrienes eluted at the retention times of leukotriene C4 (LTC4) and leukotriene D4 (LTD4). Leukotrienes 325-337 formyl peptide receptor 1 Homo sapiens 158-162 3001181-5 1986 Resolution by reverse phase high performance liquid chromatography of the products released from monocytes pretreated with cytochalasin B and stimulated with FMLP or calcium ionophore yielded a single peak of immunoreactive LTB4 eluting at the same retention time as the synthetic standard; immunoreactive C-6 sulfidopeptide leukotrienes eluted at the retention times of leukotriene C4 (LTC4) and leukotriene D4 (LTD4). Leukotrienes 325-336 formyl peptide receptor 1 Homo sapiens 158-162 3001181-7 1986 The leukotriene-generating response of monolayers of human monocytes pretreated with cytochalasin B to FMLP is receptor-mediated, as indicated by the inactivity of the structural analog N-acetyl-methionyl-leucyl-phenylalanine and by the capacity of the FMLP receptor antagonist carbobenzoxyphenylalanyl-methionine to inhibit the agonist action of FMLP in a dose-response fashion. Leukotrienes 4-15 formyl peptide receptor 1 Homo sapiens 103-107 6088878-9 1984 A competitive inhibitor of leukotriene slow-reacting substance of anaphylaxis, FPL 55712, blocked in a dose-response fashion LTB4-, C5a des arg-, and FMLP-triggered LAI. Leukotrienes 27-38 formyl peptide receptor 1 Homo sapiens 150-154 7053244-2 1981 NCD3 displayed a considerable degree of stimulus specificity in that it inhibited N-formyl-methionyl-leucyl-phenylalanine- (FMLP) induced chemotaxis up to 80%, C5a and zymosan-activated plasma induced chemotaxis by only 20% and had no effect on leukotriene B4- (LTB4) or casein-mediated chemotaxis. Leukotrienes 245-256 formyl peptide receptor 1 Homo sapiens 124-128 32707189-8 2020 Overall, our results showed that PC-PLC is critical for fMLP/B-stimulated eosinophil LT synthesis and degranulation. Leukotrienes 85-87 formyl peptide receptor 1 Homo sapiens 56-60 24370750-2 2014 The observed linear-mode trajectory pattern of neutrophils toward N-formyl-methionyl-leucyl-phenylalanine (fMLP) or Interleukin (IL)-8/CXCL8 was distinguished from random migration patterns toward leukotriene (LT) B4 or platelet activating factor (PAF). Leukotrienes 197-208 formyl peptide receptor 1 Homo sapiens 107-111 27655676-4 2016 Using an under agarose chemotaxis assay, we observed that the bacterial fMLP-induced neutrophil chemotaxis signal overrode interleukin 8 (IL-8)- and leukotriene B4 (LTB4)-induced chemotaxis signals. Leukotrienes 149-160 formyl peptide receptor 1 Homo sapiens 72-76 22816782-3 2012 The migration patterns for individual cells were tracked and quantitatively analyzed, and the results suggest a hierarchy among these chemoattractants of fMLP > CXCL8 > CXCL2 > leukotriene B(4). Leukotrienes 186-197 formyl peptide receptor 1 Homo sapiens 154-158 19508901-5 2009 PMNL were primed with lipopolysaccharide (LPS) and stimulated with the receptor-mediated agonist formyl-methionyl-leucyl-phenylalanine (fMLP) to activate the arachidonic acid pathway and the biosynthesis of leukotrienes, thromboxane and prostaglandins. Leukotrienes 207-219 formyl peptide receptor 1 Homo sapiens 136-140 10428009-13 1999 In neutrophils, thimerosal causes, besides an increase of cytosolic free calcium, an increase of formyl-methionyl-leucyl-phenylalanine (fMLP)-activated leukotriene release, and a modulation of chemotactic migration and exocytosis. Leukotrienes 152-163 formyl peptide receptor 1 Homo sapiens 136-140 18677938-1 2008 UNLABELLED: The aim of our study was to characterize the priming effect of extracellular nucleotides on reactive oxygen species (ROS) production induced by formyl-methionyl-leucyl-phenylalanine (fMLP), interleukin-8 (IL-8), leukotriene B4 (LTB4), and platelet activating factor (PAF). Leukotrienes 224-235 formyl peptide receptor 1 Homo sapiens 195-199 16313925-4 2006 Ibudilast effectively blocks lipopolysaccharide (LPS)-induced tumor necrosis factor (TNFalpha, IC50 = 6.2 microM) and N-formyl-Met-Leu-Phe (fMLP)-induced leukotriene (LT) B4 biosynthesis (IC50 = 2.5 microM) in human whole blood, which are 3 and 6-fold more potent than cilomilast, respectively. Leukotrienes 154-165 formyl peptide receptor 1 Homo sapiens 118-138 16313925-4 2006 Ibudilast effectively blocks lipopolysaccharide (LPS)-induced tumor necrosis factor (TNFalpha, IC50 = 6.2 microM) and N-formyl-Met-Leu-Phe (fMLP)-induced leukotriene (LT) B4 biosynthesis (IC50 = 2.5 microM) in human whole blood, which are 3 and 6-fold more potent than cilomilast, respectively. Leukotrienes 154-165 formyl peptide receptor 1 Homo sapiens 140-144 15527168-2 2004 We observed that PMN from a female CGD carrier, with a discrete mutation in one allele of the pg91(phox) gene and exhibiting extreme lyonization, showed a consistently and remarkably delayed PMN cytosolic calcium response to the tripeptide fMLP or leukotriene B4 (LTB4). Leukotrienes 248-259 formyl peptide receptor 1 Homo sapiens 240-244 14744809-5 2004 We report here that histamine inhibits thapsigargin- and ligand (PAF and fMLP)-induced leukotriene (LT) biosynthesis in human PMN in a dose-dependent manner. Leukotrienes 87-98 formyl peptide receptor 1 Homo sapiens 73-77 17323856-0 2007 Production of leukotriene C4 by peripheral blood leukocytes stimulated with anti-fcepsilonRI antibody, PMA, and fMLP does not correlate with irreversible airway obstruction in asthmatics. Leukotrienes 14-25 formyl peptide receptor 1 Homo sapiens 112-116 11200073-0 2001 Subthreshold concentrations of anti-proteinase 3 antibodies (c-ANCA) specifically prime human neutrophils for fMLP-induced leukotriene synthesis and chemotaxis. Leukotrienes 123-134 formyl peptide receptor 1 Homo sapiens 110-114 11200073-4 2001 Preincubation with anti-PR3 resulted in a massive amplification of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced leukotriene (LT) generation, with a marked increase in the liberation of LTB4, LTA4, and 5-hydroxyeicosatetraenoic acid (5-HETE). Leukotrienes 122-133 formyl peptide receptor 1 Homo sapiens 108-112 11200073-10 2001 We conclude that subthreshold concentrations of anti-PR3 antibodies selectively modify neutrophil responses to fMLP, with enhancement of leukotriene generation and chemotaxis, but suppression of respiratory burst and degranulation. Leukotrienes 137-148 formyl peptide receptor 1 Homo sapiens 111-115 9845549-11 1998 We hypothesize that the differential ability of PAF and fMLP to induce elastase release from surface-adherent neutrophils could arise from differential ability to generate leukotrienes, such as LTB4, and would be an appropriate mechanism for the control of elastase release during inflammation in vivo, where it is important that cytotoxic agents are not released until activated neutrophils have migrated into the extravascular tissues. Leukotrienes 172-184 formyl peptide receptor 1 Homo sapiens 56-60 9613710-4 1998 In this study we tested the hypothesis whether these inhibitors can inhibit the rise in [Ca2+]i after stimulation of human PMNL with 10(-7) M n-formyl-methionyl-leucyl-phenylalanine (FMLP), leukotriene B4 (LTB4) or platelet activating factor (PAF). Leukotrienes 190-201 formyl peptide receptor 1 Homo sapiens 183-187 7515096-9 1994 This result was consistent with the observations that these agents had no effect or caused slight enhancement of histamine or leukotriene released induced by fMLP. Leukotrienes 126-137 formyl peptide receptor 1 Homo sapiens 158-162 9453467-5 1997 In the presence of cytochalasin B, the chemotactic peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP; 0.5 microM) induced leukotriene C4 production in human eosinophils isolated in discontinuous metrizamide gradients. Leukotrienes 132-143 formyl peptide receptor 1 Homo sapiens 106-110 8656056-7 1996 The priming for leukotriene synthesis coincided with an increased capacity for the release of free arachidonic acid as measured by mass spectrometry; LPS-primed cells released 8-15 times more arachidonic acid than unprimed cells within 1 min of stimulation with fMLP. Leukotrienes 16-27 formyl peptide receptor 1 Homo sapiens 262-266 1663589-3 1991 Functions of polymorphonuclear leukocytes (PMN) such as N-formylmethionyl-leucyl-phenylalanine (fMLP)-stimulated superoxide release and fMLP/thimerosal elicited leukotriene (LT) biosynthesis are inhibited by these PDE inhibitors with the same rank order and even lower IC50-values. Leukotrienes 161-172 formyl peptide receptor 1 Homo sapiens 96-100 1312995-3 1992 However, the cytokines affected the formyl-methionyl-leucyl-phenylalanine-(FMLP)-induced formation of leukotrienes in a time-dependent manner. Leukotrienes 102-114 formyl peptide receptor 1 Homo sapiens 75-79 1312995-4 1992 Preincubation of the cells with the different cytokines for short periods (15 seconds at 37 degrees) enhanced the subsequent FMLP-induced leukotriene generation, whereas preincubation for prolonged times resulted in a reduced formation of leukotrienes. Leukotrienes 138-149 formyl peptide receptor 1 Homo sapiens 125-129 1312995-6 1992 The present study indicates a modulation of the FMLP-induced leukotriene formation by diverse cytokines via interaction with the GTP-binding proteins. Leukotrienes 61-72 formyl peptide receptor 1 Homo sapiens 48-52 1537591-5 1992 However, pretreatment of neutrophils with 10 mM neomycin followed by the addition of NaF or FMLP resulted in an enhanced generation of leukotrienes. Leukotrienes 135-147 formyl peptide receptor 1 Homo sapiens 92-96 1652553-4 1991 PMN pre-stimulated with FMLP showed a synergistically enhanced generation of leukotrienes returning to control values with the time of preincubation. Leukotrienes 77-89 formyl peptide receptor 1 Homo sapiens 24-28 1652553-7 1991 Membrane fractions isolated from FMLP-pre-stimulated neutrophils showed a pattern in [3H]Gpp (NH) p-binding capacity that was comparable to the respective leukotriene release. Leukotrienes 155-166 formyl peptide receptor 1 Homo sapiens 33-37 2045129-0 1991 Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis. Leukotrienes 66-78 formyl peptide receptor 1 Homo sapiens 30-34 2045129-6 1991 Furthermore, FMLP distinctly enhanced the leukotriene release of neutrophils from patients with AD compared to unstimulated cells and to cells of normal donors. Leukotrienes 42-53 formyl peptide receptor 1 Homo sapiens 13-17 2138998-3 1990 We have studied discrete events in the process of signal transduction: NSAIDs but not a related analgesic drug (acetaminophen), inhibited aggregation in response to the chemoattractants f-Met-Leu-Phe (FMLP), leukotriene B4, and C5a. Leukotrienes 208-219 formyl peptide receptor 1 Homo sapiens 201-205 1705512-10 1991 IL 3 also shortens the lag time and increases the rate of leukotriene generation in basophils triggered by FMLP. Leukotrienes 58-69 formyl peptide receptor 1 Homo sapiens 107-111 2154987-0 1990 Involvement of calcium in the thimerosal-stimulated formation of leukotriene by fMLP in human polymorphonuclear leukocytes. Leukotrienes 65-76 formyl peptide receptor 1 Homo sapiens 80-84 2154987-1 1990 Only small amounts of leukotrienes could be detected by reverse-phase HPLC analysis after stimulation of human polymorphonuclear leukocytes (PMN) by the receptor agonist N-formyl-methionyl-leucyl-phenylalanine (fMLP). Leukotrienes 22-34 formyl peptide receptor 1 Homo sapiens 211-215 2154987-5 1990 The formation of leukotrienes by fMLP/thimerosal required extracellular Ca2+. Leukotrienes 17-29 formyl peptide receptor 1 Homo sapiens 33-37 1937907-1 1991 Simultaneous stimulation of human neutrophils (PMN) with the receptor-mediated activator formyl-met-leu-phe (FMLP) and the G protein activator sodium fluoride (NaF) resulted in the synergistic generation of leukotrienes. Leukotrienes 207-219 formyl peptide receptor 1 Homo sapiens 109-113 2157779-7 1990 Specifically, GM-CSF enhances 3H-arachidonic acid release, synthesis of leukotriene B4 and platelet activity factor in response to fMLP and the calcium ionophores. Leukotrienes 72-83 formyl peptide receptor 1 Homo sapiens 131-135 35392553-2 2022 Here we report that the potent IRE1alpha inhibitor, KIRA6, blocks leukotriene biosynthesis in human phagocytes activated with lipopolysaccharide (LPS) plus N-formyl-methionyl-leucyl-phenylalanine (fMLP) or thapsigargin (Tg). Leukotrienes 66-77 formyl peptide receptor 1 Homo sapiens 197-201